Pathology: mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - all population; non squamous - mNSCLC - L2 - all population; squamous - mNSCLC - L2 - all population;
| mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - all population | non squamous - mNSCLC - L2 - all population | squamous - mNSCLC - L2 - all population | |||
| CheckMate 026 (PDL1>1%), 2016 | CheckMate 026 (PDL1>5%), 2016 | CheckMate 078, 2019 | CheckMate 057, 2015 | CheckMate 017, 2015 | ||
| nivolumab alone | 5 | T1 | T1 | T1 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | T0 | |||
| docetaxel | 0 | T0 | T0 | T0 | ||